WS Audiology looks to new OTC market – but won't disclose plans
As competitors are arming themselves with products designed for the upcoming OTC sales channel in the US, WSA keeps a tight lid on plans. The new market will start out messy, says CEO Eric Bernard, but it will stabilize eventually.
BY CHRISTIAN BUNDGAARD, TRANSLATED BY DANIEL PEDERSEN
On Thursday, WS Audiology could present the best quarterly report since the company was founded when Sivantos and Widex merged in 2019.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WS Audiology's revenue grows by 10 percent in Q1
For subscribers
WSA merges with its independent retailer
For subscribers
.jpg&w=384&q=75)
